Cardiff Oncology Inc (CRDF)

NASDAQ
6.710
+0.110(+1.67%)
  • Volume:
    376,442
  • Bid/Ask:
    6.700/6.720
  • Day's Range:
    6.520 - 6.800
  • Type:Equity
  • Market:United States
  • ISIN:US14147L1089
  • CUSIP:00014147L108

CRDF Overview

Prev. Close
6.6
Day's Range
6.52-6.8
Revenue
400K
Open
6.61
52 wk Range
4.89-25.5
EPS
-0.69
Volume
376,442
Market Cap
261.04M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,132,250
P/E Ratio
-
Beta
1.77
1-Year Change
-24.23%
Shares Outstanding
39,552,129
Next Earnings Date
Nov 11, 2021
What is your sentiment on Cardiff Oncology Inc?
or
Vote to see community's results!

Cardiff Oncology Inc News

Cardiff Oncology Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyNeutralStrong Sell
Technical IndicatorsSellStrong BuySellStrong SellStrong Sell
SummaryNeutralStrong BuyNeutralSellStrong Sell

Cardiff Oncology Inc Company Profile

Cardiff Oncology Inc Company Profile

Employees
12

Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.

Read More
  • about to pop
    0
    • 11.20 soon
      0
      • To the moon 🚀
        0
        • Wow its going to gain sooner
          0
          • Zman Any tips for bull?
            0
            • Zman TradingNo hopes mate
              0
            • Zman Tradinggood call👎
              0
            • Zman Trading i think its a good buy now
              0
          • https://seekingalpha.com/article/4400581-first-look-cardiff-oncology
            0
            • In green! Very important step in the right direction. Price is at +11.45% from yesterdays low!
              0
              • Higher high and higher low on the daily!
                0
            • Strong finish! Almost 10% up from todays low at $10.21. Signals further upside $$$
              0
              • What is your price predictions about today
                0
              • Jobir Avezov Right now it's testing yesterdays closing price. Most important thing today imo is to close above this price - $11.14. If so, I expect further upside. Extremely volatile atm. Impossible to predict but a close above $12 would be super bullish imo.
                0
            • Price is king, but after reading the clinical results I’m pretty sure this dump is a massive overreaction!
              0
              • Do you think it could be up coming weeks?
                0
              • Jobir AvezovYes, imo the low is in. My short term target is $14, but could go higher.
                0
              • Zman TradingOkay thanks mate
                0
            • Imo low is in at 10.75. Expecting a rebound.
              0
              • Well, almost I guess;-)
                0
            • I have no idea should I stop loss
              1
              • stop loss its exactly what they want from you, to take your loss and buy again.
                0
            • Time to #BUY !
              0
              • WTH happened?
                0
                • nothing, no news, just options expiring 😅
                  0
              • Free fall
                0
                • Nearing bottom of bullish channel: time to buy!
                  1
                  • https://www.biospace.com/article/releases/cardiff-oncology-prices-public-offering-sep-30-2020/
                    0
                    • Target 35
                      1
                      • where is this price point heading
                        0
                        • ask nostradamus
                          0
                      • Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC) Source: PR Newswire (US) SAN DIEGO, Jan. 29, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced an agreement with PoC Capital, LLC, to fund clinical development of Onvansertib, Trovagene's first-in-class, 3rdgeneration oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor in a Phase 1b/2 clinical trial in patients with metastatic Colorectal Cancer (mCRC). Trovagene submitted an Investigational New Drug (IND) application and protocol to the FDA on December 19, 2018, and received a "study may proceed" notification from the FDA, 28-days later, on January 16, 2019. The trial will be conducted at two prestigious cancer centers in the U.S.; USC Norris Comprehensive Cancer Cent
                        0
                        • San Diego, CA-based TrovaGene Inc. (NASDAQ:TROV) , a molecular diagnostic company, recently announced encouraging data pertaining to its Precision Cancer Monitoring (PCM) technology for both urine and plasma EGFR mutation testing. Notably, the results demonstrated greater detection sensitivity for PCM compared to tissue testing alone. The data will be presented in Vienna, Austria at the 17th World Conference on Lung Cancer.
                          0
                          • Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of...
                            0
                            • news out
                              0
                              • Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of...Source: PR Newswire (US)SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that its abstract highlighting data from the Company's lead clinical program in Acute Myeloid Leukemia (AML) has been accepted for presentation at the 60th American Society of Hematology (ASH) Annual Meeting, December 1-4, 2018.The presentation will include data from the ongoing Phase 1b/2 clinical trial of onvansertib (PCM-075), a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor, in combination with standard-of-care low-dose cytarabine (LDAC) or decitabine in patients with relapsed or refractory AML
                                0
                                • Every time there is some good news some smart person shorts it.. Wish I was able to
                                  0
                                  • This is ridiculous
                                    0
                                    • Can’t wait till the shorts are squeezed out
                                      0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.